This analysis reviews lipid-lowering drugs and pharmacogenomics in elderly populations, suggesting tailored treatment approaches for chronic diseases.
With the advent of an aging society in China, the elderly population is growing, and their health status and disease burden are also increasing. Cardiovascular and cerebrovascular diseases are the main killers that harm the health of the elderly. Dyslipidemia is one of the independent risk factors for the occurrence of cardiovascular and cerebrovascular diseases. Lipid-lowering drugs, as commonly used drugs to prevent cardiovascular events in clinical practice, are widely used in elderly patients. This article summarizes and categorizes several major types of drugs currently used for lipid-lowering therapy, combining the latest research progress in pharmacogenomics to provide references for lipid-lowering regimens in elderly patients.
No takes yet. Share an insight, caveat, or question.
Meng Dong (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: